Shots:
- Teva to get an exclusive license globally to develop, manufacture & commercialize anle138b &sery433. Additionally, both companies will jointly develop the products for MSA & PD based on early-stage clinical studies & will investigate additional indications based on clinical outcomes
- The P-I study of anle138b demonstrated a favorable benefit-risk profile at all doses while achieving higher plasma levels than those required for full therapeutic efficacy in animal models
- Modag’s Anle138b has been initially developed for MSA & PD & is designed to facilitate other ND disorders such as AD. Anle138b is currently being evaluated in a P-Ib clinical trial for the patient with PD
Click here to read full press release/ article | Ref: Teva | Image: Biospace
The post Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease first appeared on PharmaShots.
